An experimental targeted cancer drug has shown promising results in patients with advanced osteosarcoma, a rare and aggressive form of bone cancer that frequently affects children, teenagers, and young adults.
The treatment, known as risvutatug rezetecan (Ris-Rez), demonstrated improved disease control compared with conventional chemotherapy in a Phase 3 clinical trial.
Encouraging Clinical Trial Findings
The ARTEMIS-011 trial involved 122 patients with relapsed or treatment-resistant osteosarcoma who had previously received at least two lines of therapy.
According to results announced by Hansoh Pharma, patients receiving Ris-Rez achieved a median progression-free survival of 5.5 months, compared with 1.4 months among those receiving the chemotherapy combination gemcitabine and docetaxel.
The experimental treatment reduced the relative risk of disease progression or death by 67%.
Researchers also observed tumor responses in 15% of patients treated with Ris-Rez, compared with approximately 2% in the chemotherapy group.
A More Targeted Approach to Bone Cancer
Ris-Rez is an antibody-drug conjugate designed to recognize B7-H3, a protein found on various cancer cells.
By combining a targeted antibody with a powerful anticancer compound, the treatment aims to deliver its therapeutic effects more directly to tumor cells.
Targeted treatments are becoming increasingly important in oncology as researchers seek therapies that may improve outcomes for patients with aggressive or treatment-resistant cancers.
Readers interested in similar developments can explore HealX Magazine’s medical innovation articles, covering advances in cancer research and emerging medical technologies.
Why the Findings Matter
Osteosarcoma can be difficult to treat when it returns after chemotherapy or spreads to other parts of the body.
For patients with limited treatment options, even modest improvements in disease control can represent meaningful progress.
However, the trial findings do not yet establish whether Ris-Rez significantly extends overall survival. Additional follow-up and safety monitoring remain essential.
Researchers also reported serious adverse events associated with the treatment.
Although Ris-Rez remains investigational, the results highlight the potential of antibody-drug conjugates to improve treatment strategies for difficult-to-treat bone cancers.
